Literature DB >> 25076792

Three-Day Combination Treatment for Vulvovaginal Candidosis with 200 mg Clotrimazol Vaginal Suppositories and Clotrimazol Cream for the Vulva is Significantly Better than Treatment with Vaginal Suppositories Alone - an Earlier, Multi-Centre, Placebo-Controlled Double Blind Study.

W Mendling1, R Schlegelmilch2.   

Abstract

Problem: According to the guidelines, acute vulvovaginal candidosis (VVC) may be treated vaginally, through a combination of vaginal treatment and cream for the vulva or orally. However, there is a lack of investigations into whether combined treatment for the vagina and vulva achieves better results than vaginal treatment alone. Method: In 1999, 160 patients with vulvovaginal candidosis from ten German gynaecological practices were included in a study and treated on a randomised basis with three 200 mg clotrimazol vaginal suppositories = clotrimazol 2 % cream (verum n = 79) or + placebo (active-ingredient-free cream base n = 79). The examinations took place before treatment (T1), six to eight days following the end of treatment (T2) and approximately four weeks following the end of treatment (T3). In addition to demographic data, the clinical findings of each investigation were documented in a standardised way and a native preparation and a fungal culture were taken. The doctor and patient evaluated the healing process and tolerance. The main efficacy variables were the pre/post difference scores for extravaginal redness.
Results: On T1, there was no difference between the two groups. By T2, there was a significant difference in the extent of extravaginal redness between the verum and the placebo groups (p = 0.0002), as well as in the subgroup of the per-protocol analysis (verum 64, placebo 70 patients, p = 0.0015). Genital itching or burning had entirely disappeared in 51 % and 56 % of patients respectively in the verum group and in only 30 % and 45 % of patients in the placebo group on T2 (p = 0.0181). There was no difference in intravaginal redness on T1 and T2 in either group. The overall assessment by the doctor went accordingly (p = 0.0004). On T1, the extravaginal fungal culture was positive in 75 women in the verum group and in 76 women in the placebo group. On T2, however, this was positive in 51.9 % (verum) and 73.1 % (placebo) of cases, and a positive culture was evinced in the vagina in 6 vs. 8 women (7.5 vs. 10.1 %, p = 0.3802). The local tolerance in both groups was 70 % very good, and 29 vs. 27 % good. After four weeks (T3), 16 out of 23 patients in the verum group and only 8 out of 21 in the placebo group had negative extravaginal fungal cultures. Discussion: There is a lack of studies into the issue of whether vaginal treatment or combined vulvovaginal treatment of acute VVC would be more advantageous. However, there are two studies that support the significant results of this paper that when it comes to acute VVC, the combination of three 200 mg clotrimazol vaginal suppositories with clotrimazol cream 2 % is better than with vaginal suppositories alone.

Entities:  

Keywords:  clotrimazol cream; clotrimazol vaginal suppositories; combination treatment; vaginal candidosis

Year:  2014        PMID: 25076792      PMCID: PMC4078134          DOI: 10.1055/s-0034-1368243

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  8 in total

1.  Recurrent vulvovaginal candidosis: focus on the vulva.

Authors:  Florian C Beikert; Minh T Le; Angela Koeninger; Kristin Technau; Andreas Clad
Journal:  Mycoses       Date:  2011-05-25       Impact factor: 4.377

2.  Sexually transmitted diseases treatment guidelines, 2010.

Authors:  Kimberly A Workowski; Stuart Berman
Journal:  MMWR Recomm Rep       Date:  2010-12-17

3.  [Evaluation of the efficacity and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis].

Authors:  C Quereux; B Gelas; T Chevallier; F Petit; M C Micheletti
Journal:  Gynecol Obstet Fertil       Date:  2000-03

4.  Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis.

Authors:  Daron G Ferris; Paul Nyirjesy; Jack D Sobel; David Soper; Adriana Pavletic; Mark S Litaker
Journal:  Obstet Gynecol       Date:  2002-03       Impact factor: 7.661

5.  Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society.

Authors:  W Mendling; J Brasch
Journal:  Mycoses       Date:  2012-07       Impact factor: 4.377

6.  A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses.

Authors:  Werner Mendling; Christian Krauss; Bernward Fladung
Journal:  Mycoses       Date:  2004-04       Impact factor: 4.377

7.  Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group.

Authors:  J D Sobel; D Brooker; G E Stein; J L Thomason; D P Wermeling; B Bradley; L Weinstein
Journal:  Am J Obstet Gynecol       Date:  1995-04       Impact factor: 8.661

Review 8.  Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).

Authors:  M Nurbhai; J Grimshaw; M Watson; Cm Bond; J Mollison; A Ludbrook
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17
  8 in total
  1 in total

1.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.